Loading...
*  Clinical Utility of Serum Human Epidermal Growth Factor Receptor Type 2 Testing as a Marker of Therapeutic Response In Tissue...
Oncogene 19: 6102-6114. * Van der Geer P, Hunter T, Lindberg RA (1994) Receptor protein-tyrosine kinases and their signal ... Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive ... Fehm T, Gebauer G, Jäger W (2002) Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer ... Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: a 185-kilodalton ...
https://www.clinmedjournals.org/articles/ijccr/international-journal-of-cancer-and-clinical-research-ijccr-4-089.php?jid=ijccr
*  ADAM17: A Gatekeeper in Immune-Oncology? | ClinMed International Library | International Journal of Cancer and Clinical...
The protein disulfide isomerase ERp5 [53,54] has been shown to modulate the configuration of cell surface MICA/B and renders ... Oncogene 35: 438-447. * Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S (2009) Myeloid-derived suppressor ... ADAM17 is the major inducible sheddase for the ErbB ligands; Amphiregulin [23], TGF-α [24], Epiregulin [25], Epigen [26], HB- ... Two isoforms of FcγRIII exist CD16a and CD16b, the first a trans membrane protein the second attached to the membrane via a ...
https://clinmedjournals.org/articles/ijccr/international-journal-of-cancer-and-clinical-research-ijccr-3-058.php?jid=ijccr